Showing 1 - 10 of 17 Jun Zhang
A Randomized, Controlled, Multiregional Phase 3 Study of Ivonescimab Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer (HARMONi-3)

Status: Enrolling

Investigator: Jun Zhang

Study Coordinator: Gabrielle Hayes

Phone: 734.415.918

This is a Phase 3 Randomized, Controlled, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer. The primary e ... Read more >

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer (SUNRAY-01)

Status: Enrolling

Investigator: Jun Zhang

Study Coordinator: Derek Cole

Phone: 713.441.5607

The purpose of this study is to assess if adding LY3537982 in combination with standard of care anti-cancer drugs is more effective than standard of care in participants with untreated advanced NSCLC. NSCLC must have a change in a gene called KR ... Read more >

A151216 - Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery ALCHEMIST

Status: Open Not Enrolling

Investigator: Jun Zhang

Study Coordinator: Gabrielle Hayes

Phone: 734.415.918

This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient's tumor cells may help doctors select the best treatment ... Read more >

Comparing High-Dose Cisplatin Every Three Weeks to Low-Dose Cisplatin Weekly When Combined With Radiation for Patients With Advanced Head and Neck Cancer

Status: Enrolling

Investigator: Jun Zhang

Study Coordinator: Gabrielle Hayes

Phone: 734.415.918

This phase II/III trial compares the effect of the combination of high-dose cisplatin every three weeks and radiation therapy versus low-dose cisplatin weekly and radiation therapy for the treatment of patients with locoregionally advanced head ... Read more >

Durvalumab vs Placebo Following Stereotactic Body Radiation Therapy in Early Stage Non-small Cell Lung Cancer Patients

Status: Open Not Enrolling

Investigator: Jun Zhang

Study Coordinator: Gabrielle Hayes

Phone: 734.415.918

This is a Phase III, randomized, placebo-controlled, double-blind, multi-center study assessing the efficacy and safety of durvalumab versus placebo following SoC SBRT in patients with unresected clinical Stage I/II lymph node-negative (T1 to T3 ... Read more >

Evorpacept (ALX148) in Combination With Pembrolizumab and Chemotherapy in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-04)

Status: Open Not Enrolling

Investigator: Jun Zhang

Study Coordinator: Gabrielle Hayes

Phone: 734.415.918

This is a open-label, randomized phase 2 multi-center study of the anti-tumor efficacy of evorpacept (ALX148) + pembrolizumab + 5FU + platinum and of pembrolizumab + 5FU + platinum in patients with metastatic or unresectable, recurrent HNSCC who ... Read more >

Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

Status: Open Not Enrolling

Investigator: Jun Zhang

Study Coordinator: Gabrielle Hayes

Phone: 734.415.918

This is a open-label, randomized phase 2 multi-center study of the anti-tumor efficacy of evorpacept (ALX148) + pembrolizumab and of pembrolizumab alone in patients with metastatic or unresectable, recurrent HNSCC that is PD-L1 positive (CPS =1 ... Read more >

Integration of Immunotherapy Into Adjuvant Therapy for Resected NSCLC: ALCHEMIST Chemo-IO (ACCIO)

Status: Open Not Enrolling

Investigator: Jun Zhang

Study Coordinator: Derek Cole

Phone: 713.441.5607

This phase III ALCHEMIST trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such ... Read more >

NRG-LU005

Status: Open Not Enrolling

Investigator: Jun Zhang

Study Coordinator: Gabrielle Hayes

Phone: 734.415.918

The study is an open-label, randomized, phase III trial to evaluate the addition of atezolizumab to standard chemoradiation for limited stage small cell lung cancer. Patients will be enrolled and randomized 1:1 between chemoradiation + atezolizu ... Read more >

Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

Status: Enrolling

Investigator: Jun Zhang

Study Coordinator: Gabrielle Hayes

Phone: 734.415.918

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene ... Read more >

Phase I Trial Evaluating the Safety of the Dietary Supplement Honokiol in Early-Stage Resectable Non-Small Cell Lung Cancer

Status: Enrolling

Investigator: Jun Zhang

Study Coordinator: Derek Cole

Phone: 713.441.5607

The goal of this research study is to find the highest, safest dose of honokiol (a type of dietary supplement) that can be given to patients who have resectable early-stage NSCLC. Researchers also want to learn if giving honokiol before surger ... Read more >

Phase I Trial of Atezolizumab and Interleukin-12 Gene Therapy in Metastatic Non-Small Cell Lung Cancer With Progression on First-Line Immunotherapy With or Without Chemotherapy

Status: Open Not Enrolling

Investigator: Jun Zhang

Study Coordinator: Gabrielle Hayes

Phone: 734.415.918

This is a Phase I study evaluating the safety of atezolizumab in combination with ADV/IL-12 gene therapy in patients with metastatic non-small cell lung cancer (NSCLC) whose disease has progressed on first-line immunotherapy with or without chem ... Read more >

Phase Ib Trial of L-NMMA in Combination With Pembrolizumab in Patients With Melanoma, Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Classical Hodgkin Lymphoma, Urothelial Carcinoma, or Microsatellite Instability-High/Mismatch Repair

Status: Open Not Enrolling

Investigator: Jun Zhang

Study Coordinator: Derek Cole

Phone: 713.441.5607

The purpose of this Phase Ib study is to test the safety of NG-monomethyl-L-arginine (L-NMMA) and pembrolizumab when used together in participants with melanoma, non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), ... Read more >

Randomized Study of Erlotinib vs Observation in Patients With Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)

Status: Open Not Enrolling

Investigator: Jun Zhang

Study Coordinator: Gabrielle Hayes

Phone: 734.415.918

This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop t ... Read more >

Study of Pembrolizumab (MK-3475) Monotherapy Versus Sacituzumab Govitecan in Combination With Pembrolizumab for Participants With Metastatic Non-small Cell Lung Cancer (NSCLC)

Status: Enrolling

Investigator: Jun Zhang

Study Coordinator: Gabrielle Hayes

Phone: 734.415.918

The purpose of this study is to compare pembrolizumab (MK-3475) in combination with sacituzumab govitecan with pembrolizumab alone with respect to progression-free survival (PFS) and overall survival (OS) per Response Evaluation Criteria in Soli ... Read more >

Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adults With Untreated Metastatic Non-Squamous (NSCLC)

Status: Enrolling

Investigator: Jun Zhang

Study Coordinator: Gabrielle Hayes

Phone: 734.415.918

Livmoniplimab is an investigational drug being developed for the treatment of NSCLC. There are 2 stages to this study. In Stage 1, there are 4 treatment arms. Participants will either receive livmoniplimab (at different doses) in combination wit ... Read more >

The COVID-19 and Cancer Consortium CCC19 Registry

Status: Open Not Enrolling

Investigator: Jun Zhang

Study Coordinator:

Phone:

Cancer patients have an almost unique risk profile in this pandemic. Many patients, especially those actively on treatment, have high levels of contact with the healthcare system. Many if not all cancer patients are immunocompromised, through th ... Read more >